US5428130A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Hybrid immunoglobulins
Assignee: Genentech Inc
•
Filing: 1992-12-08
•
Granted: 1995-06-27
•
Expires: 2012-12-08
Abstract
Abstract Novel polypeptides are provided, together with methods for making and using them, and nucleic acids encoding them. These polypeptides are useful as cell surface adhesion molecules and ligands, and are useful in therapeutic or diagnostic compositions and methods.
Inventors
- 👤 Daniel J. Capon
- 👤 Laurence A. Lasky
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 18:15
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/705; A; A61; A61K; A61K38/00; C07K2319/00; C07K2319/01; C07K2319/02; C07K2319/30; C07K2319/32; C07K2319/70; C07K2319/705
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
30 words
A hybrid immunoglobulin chain comprising an amino acid sequence of a ligand binding partner protein fused, at its C-terminus, to the N-terminus of an immunoglobulin constant region amino acid sequence.
Claim 2
Dependent Claim
30 words
A hybrid immunoglobulin chain comprising an amino acid sequence of a ligand binding partner protein fused, at its C-terminus, to the N-terminus of an immunoglobulin constant region amino acid sequence.
Claim 3
Dependent Claim
26 words
The immunoglobulin chain of claim 1 wherein said immunoglobulin constant region amino acid sequence is obtained from IgG-1, IgG-2, IgG-3, IgG-4, IgE, IgA, IgD or IgM.
Claim 4
Dependent Claim
20 words
The immunoglobulin chain of claim 2 wherein said immunoglobulin constant region amino acid sequence is obtained from IgG-1 or IgG-3.
Claim 5
Dependent Claim
17 words
The immunoglobulin chain of claim 3 wherein the ligand binding partner protein and the immunoglobulin are human.
Claim 6
Dependent Claim
21 words
The immunoglobulin chain of claim 3 wherein said ligand binding partner protein and immunoglobulin amino acid sequences are from different species.
Claim 7
Dependent Claim
23 words
The immunoglobulin chain of claim 3 covalently associated with further immunoglobulin chain or chains to provide a disulfide-bonded homodimer or a disulfide-bonded homotetramer.
Claim 8
Dependent Claim
23 words
The immunoglobulin chain of claim 6 wherein the ligand binding partner is a transmembrane region-deleted or phospholipid anchor-deleted fragment of a membrane-bound receptor.
Claim 9
Dependent Claim
28 words
The immunoglobulin chain of claim 6 wherein the ligand binding partner is a membrane-bound receptor in which the transmembrane region or phospholipid anchor recognition sequence has been inactivated.
Claim 10
Dependent Claim
21 words
The immunoglobulin chain of claim 1 wherein the ligand binding partner protein amino acid sequence is incapable of cell membrane anchorage.
Claim 11
Dependent Claim
39 words
The immunoglobulin chain of claim 9 wherein the ligand binding partner protein amino acid sequence is devoid of a transmembrane region or lipid or phospholipid anchor region or has an inactivated transmembrane region or lipid or phospholipid anchor region.
Claim 12
Dependent Claim
18 words
The immunoglobulin chain of claim 9 wherein the immunoglobulin constant region sequence is from an immunoglobulin heavy chain.
Claim 13
Dependent Claim
22 words
The immunoglobulin chain of claim 11 wherein the immunoglobulin heavy chain constant region sequence comprises functionally active hinge, CH2 and CH3 domains.
Claim 14
Dependent Claim
55 words
The immunoglobulin chain of claim 12 wherein said ligand binding partner protein amino acid sequence is fused to an IgG-1 heavy chain constant region amino acid sequence beginning in the hinge region just upstream of the papain cleavage site at residue 216, taking the first residue of the heavy chain constant region to be 114.
Claim 15
Dependent Claim
20 words
The immunoglobulin chain of claim 12 wherein the immunoglobulin heavy chain constant region sequence comprises a functionally active CH1 domain.
Claim 16
Dependent Claim
56 words
A hybrid molecule comprising an amino acid sequence of a ligand binding partner protein, fused, at its C-terminus, to the N-terminus of a first immunoglobulin constant region amino acid sequence, covalently associated with a fusion of an amino acid sequence of an additional agent to the N-terminus of a second immunoglobulin constant region amino acid sequence.
Claim 17
Dependent Claim
56 words
A hybrid molecule comprising an amino acid sequence of a ligand binding partner protein, fused, at its C-terminus, to the N-terminus of a first immunoglobulin constant region amino acid sequence, covalently associated with a fusion of an amino acid sequence of an additional agent to the N-terminus of a second immunoglobulin constant region amino acid sequence.
Claim 18
Dependent Claim
18 words
The molecule of claim 16 wherein said first ligand binding partner protein and said additional agent are different.
Claim 19
Dependent Claim
27 words
The molecule of claim 16 wherein said additional agent is member of the immunoglobulin gene superfamily or is homologous to a member of the immunoglobulin gene superfamily.
Claim 20
Dependent Claim
13 words
The molecule of claim 16 wherein said covalent association is by disulfide linkage.
Claim 21
Dependent Claim
54 words
The molecule of claim 16 wherein said additional agent is selected from the group consisting of a second ligand binding protein, a multiple subunit polypeptide, a variable region or a variable region-like domain of an immunoglobulin superfamily member, a toxin and a polypeptide therapeutic agent not otherwise normally associated with an immunoglobulin constant domain.
Claim 22
Dependent Claim
19 words
The molecule of claim 19 wherein the immunoglobulin constant region amino acid sequences are from an immunoglobulin heavy chain.
Claim 23
Dependent Claim
23 words
The molecule of claim 20 wherein each of said immunoglobulin constant region amino acid sequences comprises functionally active hinge, CH2 and CH3 domains.
Claim 24
Dependent Claim
23 words
The molecule of claim 21 wherein at least one of said immunoglobulin constant region amino acid sequences comprises a functionally active CH1 domain.
Claim 25
Dependent Claim
10 words
The molecule of claim 22 comprising an immunoglobulin light chain.
References Cited (Backward Citations)
EP0125023A1
Cited
EP0173494A2
Cited
EP0207402A2
Cited
EP0271227A2
Cited
EP0288809A1
Cited
EP0294703A2
Cited
EP0308381A1
Cited
EP0308936A2
Cited
EP0314317A1
Cited
EP0322094A1
Cited
WO1989004872A1
Cited
EP0325224A2
Cited
EP0325262A2
Cited
WO1990002338A1
Cited
EP0386906A1
Cited
US5116964A
Cited
EP0391088A2
Cited
WO1991000360A1
Cited
EP0414178A2
Cited
WO1991004329A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-06-26 | 1998-12-26 | 1999-06-27 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-06-26 | 2002-12-26 | 2003-06-27 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-06-26 | 2006-12-26 | 2007-06-27 | $7700.00 | Window Closed / Lapsed |